Ann D. Rhoads

Ann D. Rhoads has served on the Board of Directors since July 2011 and is the Chairperson of the Audit Committee and a member of the Nominating and Corporate Governance Committee. Ms. Rhoads was previously the Chief Financial Officer of Forty Seven, Inc.(NASDAQ: FTSV), a clinical-stage biotechnology company from March 2018 until its acquisition by Gilead Sciences, Inc., a publicly-traded pharmaceutical company, in April 2020. Previously, Ms. Rhoads was Executive Vice President and Chief Financial Officer of Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company, from March 2010 through January 2017. From 2000 through the end of 2009, Ms. Rhoads served as the Chief Financial Officer of Premier, Inc., a healthcare supply management company.

Ms. Rhoads holds a B.S. in Finance from the University of Arkansas and an M.B.A. from the Harvard Business School. Ms. Rhoads also serves on the Board of Directors of Quidel Corporation, Repare Therapeutics, iTeos Therapeutics, and Evoke Pharma, Inc.

Ms. Rhoads’ experience as the chief financial officer of publicly-traded biotechnology and pharmaceutical companies brings valuable financial skills and expertise to the Board of Directors that includes significant executive management experience and leadership skills, and a strong understanding of corporate governance principles.